WO2007006443A1 - Extraits de ginkgo biloba - Google Patents

Extraits de ginkgo biloba Download PDF

Info

Publication number
WO2007006443A1
WO2007006443A1 PCT/EP2006/006429 EP2006006429W WO2007006443A1 WO 2007006443 A1 WO2007006443 A1 WO 2007006443A1 EP 2006006429 W EP2006006429 W EP 2006006429W WO 2007006443 A1 WO2007006443 A1 WO 2007006443A1
Authority
WO
WIPO (PCT)
Prior art keywords
extracts
opc
liquid
ginkgo
polar
Prior art date
Application number
PCT/EP2006/006429
Other languages
English (en)
Inventor
Christophe Carite
Santiago Rull Prous
Smail Alaoui Ismaili
Pedro Forner
Christine GÄRTNER
Sybille Buchwald-Werner
Original Assignee
Cognis Ip Management Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cognis Ip Management Gmbh filed Critical Cognis Ip Management Gmbh
Priority to JP2008520747A priority Critical patent/JP2009501169A/ja
Priority to BRPI0612828-9A priority patent/BRPI0612828A2/pt
Priority to CA002615031A priority patent/CA2615031A1/fr
Priority to EP06762340A priority patent/EP1906981A1/fr
Priority to US11/995,589 priority patent/US20080193572A1/en
Priority to AU2006268999A priority patent/AU2006268999A1/en
Publication of WO2007006443A1 publication Critical patent/WO2007006443A1/fr
Priority to NO20080741A priority patent/NO20080741L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to new extracts of the leaves of Ginkgo biloba, a process for obtaining said extracts and their use for making oral preparations for the application in pharmaceuticals and/or dietary supplements and/or foods (incl. functional foods, foods for particular nutritional purposes, medical foods, and the like).
  • the Ginkgo tree is a phenomenon. Darwin called it ,,a living fossil", since all of its properties are associated with longevity. Since ancient times the tree has been planted in China and Japan in temple gardens, otherwise this plant might not even exist today.
  • Ginkgo biloba is the only extant species of ginkgos today, many ginkgo relatives have been found in the fossil record.
  • the Ginkgoales are a group of gymnosperms that date back to the Permian. The group is thought to be more closely related to the conifers than any other gymnosperm.
  • the modern-day Ginkgo biloba can grow up to 30 meters and can live for a millennium. The leaves are used as a herbal medicine although the seed were used more frequently.
  • Bi-guo-ye is used to treat respiratory problems, hearing loss, couching, tuberculosis, poor circulation, memory loss, gonorrhoea, stomach pain, skin diseases, leukorrhoe, angina pectoris, dysenterie, high blood pressure, anxiety and others.
  • the powdered leaves are inhaled for asthma, ear, nose and throat disorders.
  • Ginkgo biloba extracts The main active ingredients of Ginkgo biloba extracts are flavonoids (such as quercitin, kaempferol, isorhamnetin, myricetin) and their glycosides, terpeniods (such as ginkgolides A, B, C, J, M and bilobalides), and some small phenolic compounds.
  • flavonoids such as quercitin, kaempferol, isorhamnetin, myricetin
  • terpeniods such as ginkgolides A, B, C, J, M and bilobalides
  • EP 0431535 Bl and EP 0431536 Bl are directed to extracts of the leaves of Ginkgo biloba comprising (a)20 to 30 % b.w. flavone glycosides, (b) 2.5 to 4.5 % b.w. ginkgolides A, B, C and J (in total), (c) 2.0 to 4. 0 % b.w. bilobalide, (d) less than 10 ppm alkyl phenol compounds and (e) less than 10 % b.w.
  • condensed tannins more particularly (oligomeric) proanthocyanidins (OPC), and a method for obtaining them.
  • OPC proanthocyanidins
  • the specification as claimed by Schwabe has been taken over as a standard for all pharmaceutical applications of Ginkgo extracts. Attention should be drawn to the contents of compounds (d) and (e): while the gingkolic acids are suspected to cause irritations, proanthocyanidins (OPCs) are responsible for haemaglutinating and serum precipitating properties if the Ginkgo extract is administered intravenously or intramuscularily thus circumventing the oral route.
  • the negative properties of OPC are also reported in EP 0477968 Bl (Schwabe) which discusses removing these compounds from the extracts by a special process in its entirely.
  • EP 0360556 Bl discloses in Example 1 a Ginkgo composition comprising 24 % b.w. flavone glycoside, 3.6 % b.w. ginkgolides, 3.1 % b.w. bilobalides and a so-called procyanidolic index, which is considered to be equivalent to the OPC content, of 9 % b.w.
  • Ginkgo compositions which are characterised by a reduced content of other components, like 4'0-methyl-pyridoxines, biflavones and terpene lactones.
  • the present invention claims new extracts from the leaves of Ginkgo biloba, comprising
  • the improved health benefits of the Gingko extracts with increased OPC content refers to improved antioxidant effects of the extracts, resulting in improved anti-inflammatory activity and improved beneficial effects for vascular tissues, including reduced capillary fragility and connective tissue stabilization. These are of particular relevance to eye health, by improving retinal microcirculation, accelerated resynthesis of rhodopsin, modulation of retinal enzyme activity, and others.
  • These improved benefits of Gingko extracts with increased OPC content confers benefits including but not limited to improved night vision and dark adaptation, as well as improved retinal blood flow which is relevant in diabetic retinopathy, other types of retinopathies, age-related macular degeneration and glaucoma.
  • Oligomeric proanthocyanidins also known as procyanidins, leucoanthocyanins or condensed tannins, are oligmers or polymers with flavan-3-ols such as (+)-catechin or (-)-epicatechin as forming the basic units.
  • flavan-3-ols such as (+)-catechin or (-)-epicatechin as forming the basic units.
  • Their name reflects the fact that they are converted to the coloured anthocyanidins upon acid hydrolysis.
  • the linkage between successive monomers is via C4 to C8, but may also occur via C4 to C6..
  • the structure is reflected in the following graph.
  • Another object of the invention is to provide a process for making extracts from the leaves of Ginkgo biloba, comprising
  • Such inventive process consists of the following steps:
  • said intermediate LI-2 is adjusted to a pH of 2.5 to 6.0 and next subjected to a liquid-liquid extraction with a polar C 2 -C 6 aliphatic alcohol in order to obtain an (aqueous) liquid intermediate LI-3 rich in OPC and another (organic) liquid intermediate LI-4 rich in glycosides;
  • said intermediate LI-4 is concentrated, diluted with water and mixed with non- polar C 4 -C 10 hydrocarbons in order to obtain a further (organic) liquid intermediate LI-5 and another (aqueous) liquid intermediate LI-6, while LI-5 can be dried, if necessary, in order to adjust the final terpene lactone content, (v) said liquid intermediate LI-6 is dried to give a first solid intermediate SI-I ;
  • said liquid intermediate LI-3 is separated from organic solvents, diluted with water, adjusted to a pH value of 6 to 8 and cooled to a temperature of at most 10 °C for a period sufficient to precipitate the OPC from the solution;
  • the second solid intermediate SI-2 is added to the first solid intermediate SI-I in such amount that the final product contains more than 10 % b.w. OPC.
  • the extracts obtained according to the invention typically show a content of OPC of 11 to 20, more preferably 12 to 18 and most preferably 13 to 15 % b.w. OPC. Usually, they comprise
  • the water content of the extracts is typically at most 5 % b.w.
  • a particular advantage of the new process is that one can start either from Ginkgo leaves (typically showing a content of flavone glycosides, ginkgolides and bilobalides of at least 10 % b.w.) or commercially available dry Ginkgo extracts (typically showing a content of flavone glycosides, ginkgolides and bilobalides of 5 to 20 % b.w.) in order to end up with a final product which matches the specifications, in particular shows an OPC content of more than 10, preferably about 12 % b.w.
  • the polar solvents of step (i) are acetone or ethanol. It has been found that acetone is very suitable for the extraction of the leaves, while ethanol is the preferred solvent for the extraction of the dry intermediates one can buy in the market.
  • the non-polar hydrocarbon of steps (ii) and (iv) is preferably n-heptane, which is rather useful in order to ensure that all unwanted ginkgolic acids are removed and concentrated in the organic waste phase.
  • said polar alcohol of step (iii) is preferably n-butanol.
  • the major improvement of the new process over the prior one is to separate a fraction rich in OPC from the main stream, to concentrate, purify and isolate said OPCs, and finally add them back to the main stream, in order to increase the OPC content from typically 4 to 8 % b.w. to more than 10, and typically about 12 % b.w.
  • Dried mixtures according to the present invention can also be formulated as powders, granules or semisolids for incorporation into capsules.
  • the compositions can be formulated together with any one or more excipients, or they can be presented in an undiluted form.
  • the dried mixtures can be dissolved or suspended in a viscous liquid or semisolid vehicle, such as a polyethylene glycol, or a liquid carrier, such as a glycol, e.g., propylene glycol, or glycerol, or a vegetable or fish oil, for example, an oil selected from olive oil, sunflower oil, safflower oil, soy oil and others.
  • a viscous liquid or semisolid vehicle such as a polyethylene glycol, or a liquid carrier, such as a glycol, e.g., propylene glycol, or glycerol, or a vegetable or fish oil, for example, an oil selected from olive oil, sunflower oil, safflower oil, soy oil and others.
  • Such extracts can be macro-encapsulated, that means filled into capsules of either the hard gelatine or soft gelatine type or made from hard or soft gelatine equivalents (gelatine-free), soft gelatine or gelatine-equivalent capsules preferred for viscous liquid or semisolid fillings.
  • said active compositions are microencapsulated.
  • Microcapsules are understood to be spherical aggregates with a diameter from about 0.1 to about 5 mm which contain at least one solid or liquid core surrounded by at least one continuous membrane. More precisely, they are finely dispersed liquid or solid phases coated with film-forming polymers, in the production of which the polymers are deposited onto the material to be encapsulated after emulsification and coacervation or interfacial polymerization.
  • liquid active principles are absorbed in a matrix (“microsponge") and, as microparticles, may be additionally coated with film-forming polymers.
  • microscopically small capsules also known as nanocapsules
  • multiple-core aggregates also known as microspheres, which contain two or more cores distributed in the continuous membrane material.
  • single-core or multiple-core microcapsules may be surrounded by an additional second, third, etc. membrane.
  • the membrane may consist of natural, semisynthetic or synthetic materials.
  • Natural membrane materials are, for example, gum arabic, agar agar, agarose, maltodextrins, alginic acid and salts thereof, for example, sodium or calcium alginate, fats and fatty acids, cetyl alcohol, collagen, chitosan, lecithins, gelatin, albumin, shellac, polysaccharides, such as starch or dextran, polypeptides, protein hydrolyzates, sucrose and waxes.
  • Semisynthetic membrane materials are, inter alia, chemically modified celluloses, more particularly cellulose esters and ethers, for example, cellulose acetate, ethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose and carboxymethyl cellulose, and starch derivatives, more particularly starch ethers and esters.
  • Synthetic membrane materials are, for example, polymers, such as polyacrylates, polyamides, polyvinyl alcohol or polyvinyl pyrrolidone.
  • microcapsules examples are the following commercial products (the membrane material is shown in brackets) Hallcrest Microcapsules (gelatin, gum arabic), Coletica Thalaspheres (maritime collagen), Lipotec Millicapseln (alginic acid, agar agar), Induchem Unispheres (lactose, macrocrystalline cellulose, hydroxypropylmethyl cellulose), Unicerin C30 (lactose, microcrystalline cellulose, hydroxypropylmethyl cellulose), Kobo Glycospheres (modified starch, fatty acid esters, phospholipids), Softspheres (modified agar agar), Kuhs Probiol Nanospheres (phospholipids) and Primaspheres or Primasponges (chitosan, anionic polymers).
  • compositions according to the present invention are preferred in case the actives are administered orally and should be liberated at a special part of the intestine. Therefore, a person skilled in the art can easily select the adequate encapsulation system by comparing the stability of the capsules under the pH-conditions of the respective part of the intestine. Suitable processes are disclosed for example in WO 01/01926, WO 01/01927, WO 01/01928, WO 01/01929 (Primacare) or EP 1064088 Bl (Max Planck Deutschen), which are therefore incorporated by reference.
  • Commercial application are disclosed for example in WO 01/01926, WO 01/01927, WO 01/01928, WO 01/01929 (Primacare) or EP 1064088 Bl (Max Planck Deutschen), which are therefore incorporated by reference.
  • the new extracts combine the known advantageous properties of Ginkgo extracts found in the market with new surprising features, especially for improving the overall status of the human body, especially with respect to protection against free radicals and improved retinal micro circulation. Therefore, a further object of the invention is the use of the new extracts rich in OPC for making pharmaceutical preparations and/or dietary supplements and/or foods (incl. functional foods, foods for particular nutritional purposes, medical foods, and the like), in which they may be present in amounts from 10 to 1,000 mg, preferably 30 to 500 mg and more preferably 60 to 240 mg (calculated on the final composition).
  • the extracts are administered to the body either by topical or oral application.
  • Another object of the invention is finally use of said extracts for making a medicament for the improvement of retinal micro circulation and the status of the human body.
  • Step I 1000 g of leaves of Ginkgo biloba having a content of flavone glucosides, ginkgolides and bilobalides of in total 0.8 % b.w. were placed in a stirred vessel and extracted at 50 0 C for 2 h using 5 1 of aqueous acetone (60 % w/w). The liquid phase was separated from the residue and subjected to filtration and solvent evaporation in order to give the liquid intermediate LI-I having a dry residue of about 30 % b.w. Subsequently, said phase LI-I was extracted with n- heptane in order to obtain an organic phase comprising all unwanted ginkgolic acids and a second (aqueous) liquid intermediate phase LI-2 containing the value products.
  • Step II The intermediate phase LI-2 thus obtained, after adjusting pH to 2.5-6, was subjected three times to an extraction with n-butanol in order to obtain a third (aqueous) liquid intermediate phase LI-3 rich in OPC and a fourth (organic) liquid intermediate phase LI-4, the latter being a couple of times washed with water in order to remove the unwanted by-products. Then, said phase LI-4 was concentrated in order to obtain a concentrated fraction showing a dry residue of about 20 % b.w. Afterwards, the concentrate was diluted with water to a dry residue of about 10 % b.w. and mixed with n-heptane (70:30 w/w).
  • Step III The liquid intermediate LI-3, which has been obtained in Step II, was liberated from all traces of organic solvents, diluted with water to obtain a dry residue of about 30 % b.w. and adjusted to a pH value of about 6.8 to 7.2 by adding aqueous sodium hydroxide solution. Subsequently, the liquid fraction was cooled over night to 8 0 C. The next day a precipitate mainly consisting of OPC was filtered off, washed, and dried and added to the solids obtained as the final product of Step II. The combined products showed the following specification (in brackets the average of three samples):
  • Ginkgolides 2.8 - 3.4 (3.0) % b.w.
  • ROS and RNS reactive nitrogen species
  • ROS and RNS are reactive compounds which may damage important biomolecules such as proteins, lipids, carbohydrates and DNA, if not counteracted by so-called antioxidants.
  • Some but not all ROS and RNS are free radicals, i.e., atoms or molecules containing one or more unpaired electrons. Formation of ROS and RNS occurs as an integral part of human metabolism, for example by the mitochondrial respiratory chain, during the oxidative burst of activated phagocytes as part of the normal functioning of the immune system, or by enzymes such as xanthine oxidase. Exogenous factors such as sun light, cigarette smoke, or certain environmental pollutants may contribute to the human bodies exposure to ROS and RNS.
  • ROS/RNS are counteracted by a plethora of antioxidants, and oxidative stress occurs only when this balances shifts in favour of ROS/RNS. Then, damage to vital biomolecules and biological systems may be induced, and such damage, when accumulating over long periods of time, has been implicated in the development of many degenerative diseases as well as in the process of ageing itself.
  • the antioxidative properties of active substances such as the gingko extract referred to in this invention can be measured by various tests, either in vitro or in cell culture systems or else. Each test is usually specific for a certain type of ROS and/or RNS. Because the human body is exposed to the whole spectrum of these reactive substances - also referred to as 'pro-oxidants'- it may be desirable for an antioxidant to be effective against a variety of pro-oxidants.
  • the gingko extract in order to evaluate the properties of the products, can be subjected to a variety of tests, measuring its ability to reduce radical cations (DPPH Test), its ability to scavenge hydroxyl radicals (HO # ) superoxide (O 2 *- ⁇ hydrogen peroxide (H 2 O 2 ), as well as its ab i lity to quench singlet oxygen.
  • DPPH Test radical cations
  • HO # hydroxyl radicals
  • O 2 *- ⁇ hydrogen peroxide (H 2 O 2 ) as well as its ab i lity to quench singlet oxygen.
  • the metal chelating properties can be assessed.
  • the DPPH test measures the ability of a test substance to scavenge free radicals, specifically to reduce radical cations.
  • the test uses DPPH (2,2-diphenyl-l-picrylhydrazyl), a stable radical which appears 'violet' due to its absorption maximum at 515 ran, and which is transformed into a colourless compound upon reduction by the antioxidant.
  • DPPH 2,2-diphenyl-l-picrylhydrazyl
  • Gingko extract composition (in % b.w.)
  • HO # hydroxyl radicals
  • HO* may be considered the most reactive of all ROS/RNS, so that it can attack almost all cellular compound, incl. DNA constituents such as deoxyribose.
  • HO* is generated by a mixture of ascorbic acid, H 2 O 2 , and Fe 3+ -EDTA, i.e., via the Fenton reaction (H 2 O 2 in the presence of iron).
  • HO* attacks deoxyribose, degrading it into fragments that yield a pink chromogen upon heating with thiobarbituric acid (TBA) at low pH.
  • TSA thiobarbituric acid
  • Added hydroxyl radical "scavengers” compete with deoxyribose for the hydroxyl radicals produced and diminish chromogen formation.
  • the results are given in Table II below and represent the mean of two tests.
  • ROS can be generated using the xanthine oxidase/hypoxanthin system and detected using chemo-luminescense (Luminol).
  • Singlet oxygen is an electronically excited form of molecular oxygen that may be generated in vivo either photochemically, i.e., upon exposure to light, or metabolically, for example by activated neutrophils, in the course of lipid peroxidation, and in enzymatic reactions related to anti-inflammatory mediators (prostaglandin) and detoxification (cytochrom P450 oxygenases).
  • prostaglandin anti-inflammatory mediators
  • cytochrom P450 oxygenases cytochrom P450 oxygenases
  • Gingko extract composition (in % b.w.)
  • gingko extracts with increased OPC content act as antioxidants against a variety of relevant ROS which are generated by the human body and via exogenous sources, and which contribute to oxidative stress induced damage to important biomolecules and biosystems relevant to human health. It should be well noted that the increase of advantageous properties does not simply follow a proportionality, but one can observe that there is a critical OPC concentration of about 11 to 12 % b.w.
  • the antioxidant effects of the gingko extracts with increased OPC content are displayed towards radicals in general, as demonstrated in the DPPH assay. Further, they involve scavenging of the hydroxyl radical (HO*), considered to be the most reactive of all ROS, which is generated in many pathways of human metabolism and is also thought to be the actual active principle mediating damage by superoxide (O 2 * " ) and hydrogen peroxide (H 2 O 2 ). Also, the gingko extracts with increased OPC content were shown to possess metal chelating properties, thus being able to prevent generation of ROS catalysed by transition metal ions.
  • HO* hydroxyl radical
  • ROS hydrogen peroxide
  • test results demonstrate superoxide and hydrogen peroxide scavenging and singlet oxygen ( 1 O 2 ) quenching properties of the extracts, i.e., their antioxidant activity against further ROS responsible for many aspects of free radical damage to the human bodys cells and tissues.
  • the results of the various tests clearly demonstrate that the new extracts according to the invention with their improved antioxidant activity are more suitable for use in oral preparations intended to control signs of ageing, environmental stress, inflammation, and other health conditions, specifically those related to eye health, than those extracts known from the state of the art showing a reduced OPC content
  • the dispersion was then washed with an aqueous solution containing 1% by weight of sodium lauryl sulfate and 0.5 % by weight of sodium alginate and then repeatedly with a 0.5 % by weight aqueous Phenonip solution, the oil phase being removed in the process.
  • An aqueous preparation containing 8 % by weight microcapsules with a mean diameter of 1 mm was obtained after sieving.
  • the soft capsules were introduced into a bath consisting of an aqueous 0.5 % by weight solution of calcium chloride for cross-linking and hardening of the capsule walls.
  • An aqueous preparation containing 8 % by weight microcapsules with a mean diameter of 0.25 mm was obtained after sieving.

Abstract

L'invention concerne de nouveaux extraits de feuilles de Ginkgo biloba, comprenant (a) de 20 à 30 % en poids de flavone glycosides, (b) de 2,5 à 4,5 % en poids de ginkgolides A, B, C et J (au total), (c) de 2,0 à 4,0 % en poids de bilobalides, (d) moins de 10 ppm de composés d'alkyle phénol et (e) plus de 10 % en poids de proanthocyanidines oligomériques (OPC).
PCT/EP2006/006429 2005-07-12 2006-07-01 Extraits de ginkgo biloba WO2007006443A1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2008520747A JP2009501169A (ja) 2005-07-12 2006-07-01 イチョウの抽出物
BRPI0612828-9A BRPI0612828A2 (pt) 2005-07-12 2006-07-01 extratos de ginkgo biloba
CA002615031A CA2615031A1 (fr) 2005-07-12 2006-07-01 Extraits de ginkgo biloba
EP06762340A EP1906981A1 (fr) 2005-07-12 2006-07-01 Extraits de ginkgo biloba
US11/995,589 US20080193572A1 (en) 2005-07-12 2006-07-01 Extracts of Ginkgo Biloba
AU2006268999A AU2006268999A1 (en) 2005-07-12 2006-07-01 Extracts of Ginkgo biloba
NO20080741A NO20080741L (no) 2005-07-12 2008-02-11 Ekstrakter av Ginkgo biloba

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0552158A FR2888509B1 (fr) 2005-07-12 2005-07-12 Extraits de ginkgo biloba
FR0552158 2005-07-12

Publications (1)

Publication Number Publication Date
WO2007006443A1 true WO2007006443A1 (fr) 2007-01-18

Family

ID=35966402

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/006429 WO2007006443A1 (fr) 2005-07-12 2006-07-01 Extraits de ginkgo biloba

Country Status (11)

Country Link
US (1) US20080193572A1 (fr)
EP (1) EP1906981A1 (fr)
JP (1) JP2009501169A (fr)
KR (1) KR20080023733A (fr)
CN (1) CN101222929A (fr)
AU (1) AU2006268999A1 (fr)
BR (1) BRPI0612828A2 (fr)
CA (1) CA2615031A1 (fr)
FR (1) FR2888509B1 (fr)
NO (1) NO20080741L (fr)
WO (1) WO2007006443A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR075244A1 (es) * 2009-02-04 2011-03-16 Kalamazoo Holdings Inc Composiciones y metodos para mejorar la estabilidad de alimentos, bebidas, suplementos nutricionales y cosmeticos
JP2013035820A (ja) * 2011-05-10 2013-02-21 Maruzen Pharmaceut Co Ltd Ｔｉｅ２活性化剤、血管新生抑制剤、血管の成熟化剤、血管の正常化剤、及び血管の安定化剤、並びに医薬品組成物
DE102014202318B4 (de) 2014-02-10 2016-10-06 Dr. Willmar Schwabe Gmbh & Co. Kg Verbessertes Verfahren zur Herstellung von Ginkgoextrakten
CN104352538A (zh) * 2014-12-05 2015-02-18 上海信谊百路达药业有限公司 银杏内酯组合物在制备预防/治疗青光眼药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4981688A (en) * 1988-02-24 1991-01-01 Pierre Fabre Medicament Method for obtaining an extract or Ginkgo biloba leaves
EP0431536A1 (fr) * 1989-12-04 1991-06-12 Dr. Willmar Schwabe GmbH & Co. Une méthode de préparation d'un extrait de feuilles de Ginkgo biloba
CN1073562C (zh) * 1999-02-05 2001-10-24 孙传经 超临界二氧化碳从银杏叶中萃取含有原花青素提取物的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07101850B2 (ja) * 1988-04-08 1995-11-01 日本電信電話株式会社 適応ベクトル量子化法
US5637302A (en) * 1988-09-20 1997-06-10 Indena Spa Extracts of Ginkgo biloba and their methods of preparation
DE19756848C2 (de) * 1997-12-19 2003-01-16 Schwabe Willmar Gmbh & Co Extrakte aus Blättern von Ginkgo biloba mit vermindertem Gehalt an 4'-O-Methylpyridoxin und Biflavonen
DE59908424D1 (de) * 1999-07-02 2004-03-04 Cognis Iberia Sl Mikrokapseln - I
EP1064911B1 (fr) * 1999-07-02 2004-02-04 Cognis Iberia, S.L. Microcapsules
ATE304344T1 (de) * 1999-07-02 2005-09-15 Cognis Ip Man Gmbh Mikrokapseln - iii
US6979457B2 (en) * 2001-12-28 2005-12-27 Renew Life Formulas, Inc. Food supplement formulation
JP2004123622A (ja) * 2002-10-03 2004-04-22 Toyo Shinyaku:Kk 血流改善外用剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4981688A (en) * 1988-02-24 1991-01-01 Pierre Fabre Medicament Method for obtaining an extract or Ginkgo biloba leaves
EP0431536A1 (fr) * 1989-12-04 1991-06-12 Dr. Willmar Schwabe GmbH & Co. Une méthode de préparation d'un extrait de feuilles de Ginkgo biloba
CN1073562C (zh) * 1999-02-05 2001-10-24 孙传经 超临界二氧化碳从银杏叶中萃取含有原花青素提取物的方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CLOSTRE F: "[Protective effects of a Ginkgo biloba extract (EGb 761) on ischemia-reperfusion injury]", THÉRAPIE. 2001 SEP-OCT, vol. 56, no. 5, September 2001 (2001-09-01), pages 595 - 600, XP009065509, ISSN: 0040-5957 *
DATABASE WPI Section Ch Week 200510, Derwent World Patents Index; Class B04, AN 2000-054138, XP002371797 *
DIAMOND B J ET AL: "Ginkgo biloba extract: mechanisms and clinical indications.", ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION. MAY 2000, vol. 81, no. 5, May 2000 (2000-05-01), pages 668 - 678, XP009063332, ISSN: 0003-9993 *
LANG F ET AL: "Quantitative determination of proanthocyanidins in Ginkgo biloba special extracts", PHARMAZIE 1996 GERMANY, vol. 51, no. 10, 1996, pages 734 - 737, XP009063318, ISSN: 0031-7144 *
See also references of EP1906981A1 *

Also Published As

Publication number Publication date
KR20080023733A (ko) 2008-03-14
US20080193572A1 (en) 2008-08-14
EP1906981A1 (fr) 2008-04-09
FR2888509B1 (fr) 2007-09-14
BRPI0612828A2 (pt) 2010-11-30
NO20080741L (no) 2008-02-11
FR2888509A1 (fr) 2007-01-19
CA2615031A1 (fr) 2007-01-18
JP2009501169A (ja) 2009-01-15
CN101222929A (zh) 2008-07-16
AU2006268999A1 (en) 2007-01-18

Similar Documents

Publication Publication Date Title
Gandhi et al. Recent trends of phytosomes for delivering herbal extract with improved bioavailability
US5646178A (en) Cranberry extract and biologically active compounds derived therefrom
JPH09510972A (ja) 付着抑制組成物
Vasarri et al. Anti-inflammatory properties of the marine plant Posidonia oceanica (L.) Delile
WO2009049246A1 (fr) Procédés et composition anti-glycation
JP2011514347A (ja) フェノール酸を含むアブラヤシ葉からの抽出物
US6737085B2 (en) Apocynum venetum extract for use as antidepressant
CN102086185A (zh) 一种低聚原花青素及其提取方法
Lee et al. Cytoprotective effects and mechanisms of quercetin, quercitrin and avicularin isolated from Lespedeza cuneata G. Don against ROS-induced cellular damage
WO2007006443A1 (fr) Extraits de ginkgo biloba
AU2006347125B2 (en) Antioxidant composition containing component originating in the bark of tree belonging to the genus Acacia
US9034399B2 (en) Dietary compositions for promoting brain health
WO2000067768A1 (fr) Compositions permettant de guerir l'hypofecondite
ES2301748T3 (es) Preparacion antioxidante para la administracion oral y/o topica.
Ginting et al. In Vivo study of Antidiabetic Activity from Ethanol Extract of Clitoria ternatea L. Flower
Kriplani et al. Physicochemical and biological aspects of Curcumin: A review
Nagalievska et al. Red Wine and Yacon as a source of bioactive compounds with antidiabetic and antioxidant potential
JP2000128798A (ja) 活性酸素消去作用剤およびアルドースリダクターゼ阻害作用剤
CA2482236A1 (fr) Composition destinee a prevenir l'arteriosclerose
EP1541037A1 (fr) Composition orale contenant un extrait de Passiflora incarnata
Poudyal et al. A Comprehensive Review on Phytosomes: A Novel Drug Delivery System of Phytoconstituents.(2022)
JP2006151922A (ja) アントシアニン吸収促進剤
Kumari et al. PHYTOSOMES: A NOVEL DRUG DELIVERY SYSTEM FOR POLY-PHENOLIC PHYTO-CONSTITUENTS
KR20170117559A (ko) 체중 관리용 농축물 및 슬리밍 워터 그리고 이로부터 유래한 제품을 제조하기 위한, 가르시니아 캄보지아 추출물의 표준화되고 삼중염 안정화된 (-)-하이드록시시트르산을 보유하는 체중감량용 아쿠아 농축물 (slim and aqua concentrate)
JP4847712B2 (ja) アカシア属樹皮由来物を含有する抗酸化組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006762340

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006268999

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2615031

Country of ref document: CA

Ref document number: 200680025381.2

Country of ref document: CN

Ref document number: 1020087000849

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 11995589

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008520747

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: DE

ENP Entry into the national phase

Ref document number: 2006268999

Country of ref document: AU

Date of ref document: 20060701

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006268999

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2006762340

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0612828

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080109